Northland Securities cut shares of Sensus Healthcare (NASDAQ:SRTS) from an outperform rating to a market perform rating in a research note released on Monday morning, The Fly reports.
A number of other equities analysts have also recently issued reports on SRTS. started coverage on Sensus Healthcare in a report on Friday, July 6th. They issued a buy rating and a $12.25 target price for the company. Roth Capital started coverage on Sensus Healthcare in a research note on Wednesday, August 1st. They set a buy rating and a $12.50 price objective for the company. HC Wainwright started coverage on Sensus Healthcare in a research note on Monday, August 27th. They set a buy rating and a $14.00 price objective for the company. Maxim Group increased their price objective on Sensus Healthcare from $9.00 to $10.00 and gave the stock a buy rating in a research note on Wednesday, September 19th. Finally, B. Riley started coverage on Sensus Healthcare in a research note on Wednesday, September 26th. They set a buy rating and a $12.50 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $12.25.
NASDAQ:SRTS opened at $6.47 on Monday. Sensus Healthcare has a 12-month low of $4.91 and a 12-month high of $8.88. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.80 and a quick ratio of 3.49. The stock has a market capitalization of $134.80 million, a P/E ratio of -24.14 and a beta of -1.29.
In other news, insider Joseph C. Sardano sold 6,170 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $7.50, for a total transaction of $46,275.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 12,854 shares of company stock valued at $96,567. Company insiders own 41.10% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of Sensus Healthcare by 141.1% during the second quarter. Renaissance Technologies LLC now owns 27,488 shares of the company’s stock worth $200,000 after buying an additional 16,088 shares in the last quarter. Paradigm Capital Management Inc. NY acquired a new stake in Sensus Healthcare during the 2nd quarter valued at $152,000. BlackRock Inc. acquired a new stake in Sensus Healthcare during the 2nd quarter valued at $164,000. Commonwealth Equity Services LLC acquired a new stake in Sensus Healthcare during the 1st quarter valued at $140,000. Finally, Perkins Capital Management Inc. acquired a new stake in Sensus Healthcare during the 2nd quarter valued at $1,792,000. 7.25% of the stock is owned by institutional investors.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Story: How Buying a Call Option Works
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.